Compare ARRY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | ANAB |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2015 |
| Metric | ARRY | ANAB |
|---|---|---|
| Price | $7.97 | $59.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $10.21 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 6.2M | 497.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.56 | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,141,000.00 | $234,603,000.00 |
| Revenue This Year | $15.72 | N/A |
| Revenue Next Year | $8.08 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.22 | ★ 157.01 |
| 52 Week Low | $5.39 | $17.11 |
| 52 Week High | $12.23 | $73.30 |
| Indicator | ARRY | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 55.05 |
| Support Level | $7.78 | $43.75 |
| Resistance Level | $8.17 | $67.69 |
| Average True Range (ATR) | 0.66 | 2.84 |
| MACD | -0.01 | 0.99 |
| Stochastic Oscillator | 41.35 | 75.37 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).